Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.62 |
| ▸ | LMNA | P02545 | 1/20 | 0.62 |
| ▸ | MAOB | P27338 | 5/20 | 0.55 |
| ▸ | MAOA | P21397 | 4/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL705947 | 0.82 | MAOB (0.79) | ALDH1A1LMNAMAOBMAOAHPGD | |
| SCHEMBL30248834 | 0.77 | ALDH1A1 (1.00) | ALDH1A1LMNAMAOBMAOAHPGD | |
| SCHEMBL750896 | 0.77 | ALDH1A1 (1.00) | ALDH1A1LMNAMAOBMAOAHPGD | |
| SCHEMBL16412941 | 0.74 | ALDH1A1 (0.62) | ALDH1A1LMNAMAOBMAOAHPGD | |
| SCHEMBL3254310 | 0.73 | ALDH1A1 (0.90) | ALDH1A1LMNAHPGDHTTKMT2A | |
| SCHEMBL4286520 | 0.72 | HTT (0.75) | ALDH1A1LMNAMAOBMAOAHPGD | |
| SCHEMBL15631693 | 0.71 | MAOB (1.00) | ALDH1A1LMNAMAOBMAOAHTT | |
| SCHEMBL434490 | 0.70 | EPHX2 (0.77) | ALDH1A1LMNAMAOBMAOAHPGD | |
| SCHEMBL23781330 | 0.70 | HTT (0.77) | ALDH1A1LMNAMAOBMAOAHPGD | |
| SCHEMBL13545258 | 0.70 | ALDH1A1 (0.57) | ALDH1A1LMNAMAOBMAOAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7842688-B2 | Organic compounds | NOVARTIS PHARMA AG (CH) | 2010-11-30 | — | — | US | disclosed |
| US-7790715-B2 | Organic compounds | NOVARTIS AG (CH) | 2010-09-07 | — | — | US | disclosed |
| US-20090012055-A1 | Organic compounds | HEROLD PETER | 2009-01-08 | — | — | US | disclosed |
| EP-1961752-A2 | Piperidine Compounds | Speedel Experimenta AG (CH) | 2008-08-27 | — | — | EP | disclosed |
| US-20070010511-A1 | Organic compounds | NOVARTIS PHARMA AG (CH) | 2007-01-11 | — | — | US | disclosed |
| EP-1670760-A1 | ORGANIC COMPOUNDS | Speedel Experimenta AG (CH) | 2006-06-21 | — | — | EP | disclosed |
| WO-2005061457-A1 | ORGANIC COMPOUNDS | SPEEDEL EXPERIMENTA AG (CH) | 2005-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012055-A1 | Organic compounds | REN, ACE, ACE2 | ALDH1A1 142/4885LMNA 3190/4885MAOB 43/4885 |
| US-20070010511-A1 | Organic compounds | REN, ACE, ACE2 | ALDH1A1 142/4885LMNA 3190/4885MAOB 43/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.